Embracing Cultural Diversity in the Workplace.pptx

An intellectual insight on workplace diversity and inclusiveness.

1. PFIZER Inc. Technology Initiatives August 26 , 2019 1

2. 2 Business Description Business Overview Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Innovative Health focuses on developing and commercializing medicines and vaccines that improve patients' lives. Innovative Health therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. Essential Health includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. Essential Health also includes a research and development (R&D) organization as well as its contract manufacturing business. The company was incorporated in the state of New York in 1842 and sold its product in over 125 countries and employs ~ 92400 people. Head Office 235 East 42nd Street New York New York, 10017 United States [phone] Lidia Fonseca Executive Vice President, Chief Digital and Technology Officer

3. 3 Business Segments Essential Health (EH) – Performance EH segment reported revenue of US$20,221.0 million for FY2018, which decreased 4.3% YoY , and recorded negative growth of 7.5% during 2016-18. The segment accounted for 37.7% of the company's revenue in FY2018. The segment reported 31.5% of its revenue from the US and 68.5% from international markets in FY2018. In FY2018, Legacy Established products accounted for 52.1% of the EH segment revenue, followed by sterile injectable pharmaceuticals for 25.8%; Peri -LOE Products for 14.6%; biosimilars for 3.8% and Pfizer CentreOne for 3.7%. EH segment revenue in FY2018 decreased due to decline in performance of legacy established products, sterile injectable pharmaceuticals and peri -LOE products. Innovative Health (IH) – Performance IH segment reported revenue of US$33,426.0 million for FY2018, which grew 6.4% YoY , and recorded a CAGR of 7.0% during 2016-18. The segment accounted for 62.3% of the company's revenue in FY2018. The segment reported 56.7% of its revenue from the US and 43.3% from international markets in FY2018. In FY2018, IH segment reported 29.9% of its revenue from internal medicine; 21.6% from cancer; 18.9% from vaccines; 12.2% from inflammation and immunology; 10.8% from consumer healthcare; and 6.6% from rare disease. Segment revenue growth in FY2018 was primarily driven by major brands such as Eliquis , Ibrance , Prevnar 13/ Prevenar 13 and Xeljanz (globally).

4. 4 Company’s Financial Performance Revenue by Segment and Geography ($billion of dollars) Financial information as of FY Dec 2018 IH 2018 IH 2017 IH 2016 EH` 2018 EH 2017 EH 2016 Pfizer` 2018 Pfizer 2017 Pfizer 2016 U.S. International Total An increased Diluted EPS RETURNED OVER $12.3bn to shareholders through dividends and share repurchases in 2016

5. 5 Strategic Imperatives 1 Innovate and Lead Improve Pfizer's ability to innovate in biomedical R&D and develop a new generation of high value, highly differentiated medicines and vaccines 2 MAXIMIZE VALUE Invest and allocate our resources in ways that create the greatest long-term returns for our shareholders 3 Earn Greater Respect Earn society's respect by generating breakthrough therapies, improving access, expanding the dialogue on health care and acting as a responsible corporate citizen 4 Own Our Culture Build and sustain a culture where colleagues view themselves as owners, generating new ideas, dealing with problems in a straightforward way, investing in open and candid conversations and working as teammates on challenges and opportunities

6. 6 R&D Overview R&D activities focus on providing innovative products in the areas of biosimilars , immune disorders and inflammation, cardiovascular and metabolic diseases, cancer, neurological diseases, rare diseases and vaccines. In FY2018, the company spent US$8,006 million on R&D activities , which as a percentage of revenue stood at 14.92%. As of January 29, 2019, Pfizer had 100 Projects in clinical research and development including 54 NMEs, 41 additional indications and five biosimilars . Its R&D platforms include Gene Therapy, Medical Sciences, Precision Medicine and Biosimilars . It has R&D collaborations with Cystic Fibrosis Foundation Therapeutics (CFFT), Centers for Therapeutic Innovation (CTI) and National Center for Advancing Translational Sciences (NCATS). It has R&D facilities in Massachusetts, California, Missouri, Connecticut and New York in the US; and Cambridge and Sandwich in the UK. Owns numerous US and foreign patents covering pharmaceutical and other products and their uses, product manufacturing processes, pharmaceutical formulations and intermediate chemical compounds used in manufacturing. Revenues by Operating Segment and Geography

7. 7 Business Development Initiatives Invested Half Billion Dollars To Advance State-of-the-art Gene Therapy Facility In Sanford, North Carolina On August 21, 2019, acquired an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina This facility would expand the company’s presence in North Carolina, the expanded facility is projected to add approximately 300 new jobs Completed Acquisition Of Array Biopharma On July 30, 2019, completed the acquisition of Array Biopharma Strengthens Pfizer’s innovative biopharmaceutical business and category leadership in Oncology Expected acceleration of Pfizer’s long-term growth trajectory through new medicines, including the breakthrough combination of BRAFTOVI® and MEKTOVI ® Agreement To Form A New Consumer Healthcare Joint Venture (IH) On December 19, 2018, announced to enter into a definitive agreement with G`SK under which we and GSK agreed to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare name Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) On February 3, 2017, completed the sale of our global infusion systems net assets, HIS, to ICU Medical In connection with this transaction, recognized pre-tax income of $1 million in 2018 and pre-tax losses of $55 million in 2017 in Other (income)/deductions––net Acquisition of AstraZeneca’s Small Molecule Anti- Infectives Business (EH) On December 22, 2016, acquired the development and commercialization rights to AstraZeneca’s small molecule anti- infectives business, primarily outside the U.S. The total fair value of the consideration transferred for this business was approximately $1,040 million, inclusive of cash paid and the fair value of contingent consideration

8. 8 Acquisition of Medivation , Inc. (IH) On September 28, 2016, acquired Medivation for $81.50 per share Medivation’s portfolio includes Xtandi ( enzalutamide ), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells, and talazoparib , approved by the FDA in October 2018, under the trade name Talzenna and others Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P. On November 1, 2016, announced the discontinuation of the global clinical development program for bococizumab . Acquisition of Bamboo Therapeutics, Inc. (IH) On August 1, 2016, acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions Research and Development Arrangement with RPI Finance Trust In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma , under which RPI would fund up to $300 million in development costs related to certain Phase 3 clinical trials of Pfizer’s Ibrance ( palbociclib ) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication) Business Development Initiatives

9. 9 Technological Efforts… I nitiating an enterprise-wide digital effort to help speed up drug development, enhance patient and physician experiences and access and leverage technology and robotics to simplify and automate our processes Advances in both biological science and digital technology that are enhancing the delivery of breakthrough new medicines ; and the increasingly significant role of hospitals in healthcare systems Work in close collaboration with its Global Product Development organization (GPD), which has expertise in various disciplines such as Biostatistics, Clinical Pharmacology and Digital Medicine GPD also helped to enable more efficient and effective development and enhance Pfizer’s ability to accelerate and progress assets through its pipeline Strong focus across the grants on strengthening local healthcare systems and building capacity, including through primary healthcare delivery and the integration of innovative health technologies in low-resource settings The Pfizer Foundation’s flagship GHIG program (managed in partnership with Innovations in Healthcare ( IiH ), a nonprofit organization hosted by Duke University) GHIG program combines grant investments with technical support to help accelerate global health innovations by giving partners the autonomy to navigate the unique and fluid challenges they face in their local – and often last mile – communities Invested half billion dollars to advance state-of-the-art gene therapy facility in sanford , north carolina Investment will further strengthen Pfizer’s leadership in gene therapy manufacturing technology and would increase Sanford’s high-tech manufacturing environment

10. 10 Technological Efforts Opened new state-of-the-art biologics clinical manufacturing facility in andover , massachusetts The new ACMF is a multiproduct manufacturing facility with a flexible design that allows clinical products to be manufactured more efficiently and fully enable next-generation manufacturing technologies Ochsner Health System and P fizer partnered to develop innovative models for clinical trials “ Partnering with Pfizer allows us to transform medicine by creating a digital clinical trial experience that improves patient participation, integration, communication and accessibility .” Alliance supports participating patients the opportunity to test of its new digital tools designed to make the clinical trial experience more inclusive and enjoyable Towards accelerating and improving its digital capabilities Pfizer recently appointed Lidia Fonseca ( organization’s first digital officer) who will be responsible in creating and implementing its strategy to foster the business growth and to compete with its rivals to deliver more values to patients As a part of its digital transformation strategy, the company modernized most of its 35 enterprise products, migrating them to the cloud By improving their efficiency, the company has been able to reduce operating costs for both the IT department and the whole organization by about $1.5 billion Center of Excellence of analytics is an award-winning initiative, using numerous pools of clinical data to create more efficient medicine In 2011, the company made a big bet on the Internet of Things developing an experimental Parkinson’s treatment By collaborating with the IBM Watson team, the company was developing a sensor-enabled remote patient monitoring system that would make it possible to track patient health and activity in their day-to-day life outside of the clinical trial labs

11. 11 Digital Initiatives Pfizer, Concerto HealthAI join up for precision medicine partnership The partnership will use the AI platform to gain faster actionable insights for Pfizer‘s investigational therapies and commercialized therapeutics for treatment of solid tumors and hematologic malignancies, officials said. Pfizer is working with Boston-based Concerto HealthAI for a collaboration that will apply Concerto's eurekaHealth artificial intelligence technology to precision oncology research. Pfizer eyes AI-powered drug discovery and development software Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with Cambridge, Massachusetts-based XtalPi will see the firms work on molecular modelling software that can be applied to drug-like small molecules. Charlotte Allerton , Pfizer’s head of medicine design, said: “The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. “We are looking forward to potentially utilising new tools to increase our effectiveness in small molecule drug discovery and development .” Digitizing the supply chain: Why Pfizer is investing in IoT , drones and personalized medicine Within organization Pfizer is constantly looking at opportunities to further digitize the supply chain, in the scope of a journey which started several years ago and marked already very important milestones. The ultimate goal is to create a highly orchestrated supply network, which guarantees full end-to-end visibility, not just to its internal stakeholders, but also to its patients. As you can imagine, this is particularly critical in an industry where a product must not only satisfy customer demand, but also be capable at times of saving human lives. Digitizing the supply chain: Why Pfizer is investing in IoT , drones and personalized medicine Within organization Pfizer is constantly looking at opportunities to further digitize the supply chain, in the scope of a journey which started several years ago and marked already very important milestones. The ultimate goal is to create a highly orchestrated supply network, which guarantees full end-to-end visibility, not just to its internal stakeholders, but also to its patients. As you can imagine, this is particularly critical in an industry where a product must not only satisfy customer demand, but also be capable at times of saving human lives.

12. 12 Digital Initiatives Leading a Transformative Approach to Precision Medicine Working with IBM Health Watson fuels our immune-oncology research One of the major recent advances in the battle against cancer has been immune-oncology , which uses the body’s immune system to fight the disease. The future of immune-oncology may lie in combining therapies and tailoring them to unique tumor characteristics. Yet, the number of potential therapy combinations is almost impossible to quantify, let alone test. Therefore, one of the great challenges in immune-oncology is to find ways to narrow the field of focus so we can more efficiently identify effective combinations. To accelerate its work in this space, Pfizer is working with IBM Health Watson. Pfizer, other pharmacy companies join block chain project According to Block chain News, to reduce costs, errors and inefficiencies, Pfizer and other pharmaceutical companies have joined a block chain project led by technology company Chronicle. The MediLedger Project is an initiative that aims at building block chain-based ecosystems and supply chain solutions. McKesson Corp., AmerisourceBergen Corp., and Premier are the other companies that will be part of the block chain project. The block chain network expects to go live in the second quarter of this year. In earlier testing, the request and response time averaged to less than 400 milliseconds. MediLedger also established a protocol for saleable return drug verification that meets the FDA's 2019 Drug Supply Chain Security Act regulations. Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain Management Leading life sciences and healthcare companies Pfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have all joined a working group that is using blockchain technology to dramatically improve the complex process of chargeback's. “Chargeback's in healthcare are not a regulatory driven problem, but rather a business inefficiency. Last summer we came together with a smaller set of companies to build a prototype to solve some of the problems that happen today between contracting and chargeback's. We are excited to announce the addition of leading healthcare companies to the working group,” Susanne Somerville, Chronicle's CEO, told me.”

13. “Big data” and analytics bring new insights and huge opportunity to drive innovation Data will help scientists to more efficiently develop medicines and better define which patients will benefit most from specific treatments and vaccines 13 Strategy/Imperative $ 200bn Analytics can reduce health care expenditures by $200 billion in the U.S. alone by the end of the decade. Pfizer uses data at all stages of the research and development process to help discover potential medicines, assess efficacy in clinical trials and help ensure manufacturing and supply chain excellence $7.7bn In 2017 company invested into researching and developing new treatments At Pfizer, it does not only collaborate with academia and patient organizations to share expertise in a common area, but also work with other companies to potentially accelerate new innovations and therapies The company uses data at all stages of the research and development process to help discover potential medicines, assess efficacy in clinical trials and help ensure manufacturing and supply chain excellence . Leader in transforming the way researchers approach clinical trials. Company readily embrace cutting-edge technology, strategies and partnerships to ensure our high-quality clinical trials are conducted with speed and agility, and to maximize its ability to bring innovative medicines and vaccines to patients as quickly a s technologies evolve In the past five years, we invested $2.1 billion in U.S. manufacturing and our 15 U.S . manufacturing sites, employing more than 11,000 people, help produce almost 60 percent of our medicines .

14. 14 Manufacturing & Supply Chain Excellence Purpose is to bring innovative medicines and vaccines to patients and healthy individuals In 2017, continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines Under Pfizer Global Supply (PGS), company harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. Continue to use operational and supply chain data from enterprise systems to identify processes to better meet the needs of patients In 2017, this information helped company to address drug shortages of several injectable medicines used in hospitals and other clinical settings Pfizer and local political leaders joined Sanford, North Carolina, colleagues to celebrate expansion plans for the new state-of-the-art gene therapy facility under construction. The event featured a View Into the Future, including an exhibit and virtual tour of the future manufacturing facility.

15. 15 Merger & Acquisitions Announced Date Closed Date Transaction Type Role Target Buyer/Investors Sellers Size (US $ Million ) Jul-29-2019 - Merger/Acquisition Seller Upjohn Inc. Mylan N.V. (NasdaqGS:MYL) Pfizer Inc. - Jun-17-2019 Jul-29-2019 Merger/Acquisition Buyer Array BioPharma Inc. Pfizer Inc. (NYSE:PFE) 11,499.34 May-08-2019 Jul-01-2019 Merger/Acquisition Buyer Therachon AG Pfizer Inc. (NYSE:PFE) 810.0 Mar-20-2019 Mar-20-2019 Merger/Acquisition Buyer Vivet Therapeutics SAS Pfizer Inc. (NYSE:PFE) 51.1 Sep-25-2018 Sep-25-2018 Merger/Acquisition Seller NextWave Pharmaceuticals Inc Tris Pharma , Inc. Pfizer Inc. - Jul-13-2018 Jul-13-2018 Merger/Acquisition Seller Office Buildings At 219 and 235 East 42nd Street in Manhattan Alexandria Real Estate Equities, Inc. (NYSE:ARE); David Werner Real Estate Investments; Deutsche Bank AG, New York Branch, Asset Management Arm Pfizer Inc. (NYSE:PFE) 357.0 M&A’s activity of Pfizer in last two years.

16. 16 Merger & Acquisitions Announced Date Closed Date Transaction Type Role Target Buyer/Investors Sellers Size (US $ Million ) Dec-26-2017 Feb-13-2018 Merger/Acquisition Seller Sucampo Pharmaceuticals, Inc. Mallinckrodt plc (NYSE:MNK) Alexandria Real Estate Equities, Inc .; Bay City Capital LLC; BlackRock Fund Advisors; ING Groep NV, Insurance and Banking Investments; Lundbeckfond Invest A/S; New Enterprise Associates; Pfizer Inc . ; S&R Technology Holdings, LLC; Sachiko Kuno Foundation, Inc., Endowment Arm Seller Funds : 1,220.64 Nov-10-2017 Nov-10-2017 Merger/Acquisition Seller Hisun -Pfizer Pharmaceuticals Co., Ltd Hillhouse Capital Management, Ltd. Pfizer Inc. 286.0 Aug-08-2017 Dec-31-2017 Merger/Acquisition Seller Pfizer Inc., Sterile Manufacturing Facility in Liscate, Italy Avara Pharmaceutical Services, Inc. Pfizer Inc. - Jul-11-2017 Aug-28-2017 Merger/Acquisition Seller Protein Sciences Corporation Sanofi Pasteur Inc. Johnson & Johnson; Mertiva AB ( publ ); Pfizer Inc . ; Ropart Asset Management Funds 750.0 Jul-04-2017 Aug-16-2017 Merger/Acquisition Seller Laboratório Teuto Brasileiro S.A. Pfizer Inc. - May-04-2017 Apr-04-2017 Merger/Acquisition Seller Rives de Paris located in the 'Zac Francois Ory' AXA Real Estate Investment Managers SGP; AXA Selectiv´Immo Pfizer Inc. - M&A’s activity of Pfizer in last two years.